CRISPR-CAS9 TEXNOLOGIYASI: GEN TAHRIRINING BIOKIMYOVIY ASOSLARI VA TIBBIYOTDAGI QO‘LLANILISHI
Keywords:
CRISPR-Cas9, gen tahriri, Cas9 oqsili, yo‘naltiruvchi RNK, genom muhandisligi, irsiy kasalliklar, saraton terapiyasi, molekulyar biologiya, genetik davolash, bioetikaAbstract
CRISPR-Cas9 texnologiyasi zamonaviy gen muhandisligi va molekulyar biologiya sohalarida inqilobiy o‘zgarishlarga sabab bo‘lgan. Ushbu maqolada texnologiyaning biokimyoviy asoslari, ya’ni Cas9 oqsili va yo‘naltiruvchi RNKning o‘zaro ta’siri, DNKdagi ikki zanjirli uzilishlarning yuzaga kelishi va hujayraviy tuzatish mexanizmlari keng yoritilgan. Shuningdek, CRISPR-Cas9 texnologiyasining tibbiyotda qo‘llanilishi – irsiy kasalliklarni davolash, saraton terapiyasi, neyrodegenerativ va infektsion kasalliklarda genetik tahrir orqali davo topish imkoniyatlari tahlil qilingan. Maqolada texnologiyaning afzalliklari bilan birga bioxavfsizlik, “off-target” effektlar va bioetik masalalar ham ko‘rib chiqilgan. CRISPR-Cas9 kelajak tibbiyotining asosiy vositalaridan biri sifatida muhim ahamiyatga ega bo‘lib, uning mas’uliyatli va muvozanatli qo‘llanilishi global sog‘liqni saqlash tizimi uchun muhim sanaladi.
Downloads
References
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821.
Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262–1278.
Komor AC, Badran AH, Liu DR. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell. 2017;168(1-2):20–36.
Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nature Biotechnology. 2016;34(9):933–941.
Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Molecular Therapy. 2016;24(3):430–446.
Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nature Medicine. 2015;21(2):121–131.
Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, et al. Precise correction of the DMD mutations in patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports. 2015;4(1):143–154.
Manghwar H, Lindsey K, Zhang X, Jin S. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing. Trends in Plant Science. 2019;24(12):1102–1125.
Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nature Reviews Genetics. 2014;15(5):321–334.
Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proceedings of the National Academy of Sciences. 2012;109(39):E2579-E2586.
Xu X, Chemparathy A, Zeng L, Kempton HR, Shang S, Nakamura M, et al. Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing. Molecular Cell. 2021;81(24):4333–4345.e4.
Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280–284.
Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910–918.
Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nature Methods. 2013;10(11):1116–1121.
